Photoacoustic and Ultrasonic Imaging

SEP 10, 2026 · JOURNAL ARTICLE

Programmable Organic A2S-TT NPs for NIR-II/Photoacoustic Imaging-Enabled Precision Therapy

Pharmaceutics

Preclinical proof-of-concept study in cell and mouse models of a novel nanoparticle platform; no human data, efficacy metrics lack quantitative comparison to standard therapy, and no phase 1 translation reported.

SEP 9, 2026 · JOURNAL ARTICLE

GV21 enables ultrasound molecular imaging of tumor cell-associated VEGFR2 for early therapy assessment

Materials Today Bio

First-in-concept preclinical development of a novel imaging agent with no clinical efficacy or safety data, surrogate endpoint (imaging signal), and no controlled comparison of therapeutic outcomes.

SEP 8, 2026 · JOURNAL ARTICLE

Rational Design of a Smart Phototheranostic Nanoagent Based on a NIR-II-Conjugated Polymer for Highly Tumor-Specific Multimodal Imaging-Guided Synergistic Therapy

Acs Applied Materials & Interfaces

This is a preclinical materials science study reporting rational design and in vitro/in vivo characterization of a nanoagent; it raises mechanistic questions about nanoparticle performance but does not test efficacy against a comparator in any clinical or disease model.

AUG 13, 2026 · JOURNAL ARTICLE

Co-Encapsulation of Indocyanine Green J-Aggregate and Paclitaxel in Biodegradable Polymersomes for Photoacoustic-Guided Chemotherapy

Acs Applied Bio Materials

Early-stage in vitro work demonstrating proof-of-concept for a nanotheranostic platform in cell models; no animal or clinical data reported, and efficacy claims are based on cultured TNBC cells without in vivo validation or comparative clinical outcomes.

AUG 8, 2026 · JOURNAL ARTICLE

Dual-organelle–coordinated sonodynamic nanoplatform amplifies immunogenic cell death to drive robust antitumor immunity in cold tumors

Journal of Nanobiotechnology

Early-stage preclinical and patient-derived organoid study of a novel nanoplatform with promising mechanistic data but no clinical trial evidence and reliance on mouse models for efficacy claims.